PT80239B - Processo para a preparacao de novos polipeptideos fisiologicamente activos no homem e de composicoes farmaceuticas que os contem - Google Patents

Processo para a preparacao de novos polipeptideos fisiologicamente activos no homem e de composicoes farmaceuticas que os contem

Info

Publication number
PT80239B
PT80239B PT80239A PT8023985A PT80239B PT 80239 B PT80239 B PT 80239B PT 80239 A PT80239 A PT 80239A PT 8023985 A PT8023985 A PT 8023985A PT 80239 B PT80239 B PT 80239B
Authority
PT
Portugal
Prior art keywords
polympeptidees
men
contain
pharmaceutical compositions
physiologically active
Prior art date
Application number
PT80239A
Other languages
English (en)
Portuguese (pt)
Other versions
PT80239A (en
Original Assignee
Asahi Chemical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Ind filed Critical Asahi Chemical Ind
Publication of PT80239A publication Critical patent/PT80239A/pt
Publication of PT80239B publication Critical patent/PT80239B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Image Analysis (AREA)
PT80239A 1984-04-06 1985-04-04 Processo para a preparacao de novos polipeptideos fisiologicamente activos no homem e de composicoes farmaceuticas que os contem PT80239B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/597,372 US4879226A (en) 1984-04-06 1984-04-06 Novel human physiologically active polypeptide

Publications (2)

Publication Number Publication Date
PT80239A PT80239A (en) 1985-05-01
PT80239B true PT80239B (pt) 1988-02-17

Family

ID=24391235

Family Applications (1)

Application Number Title Priority Date Filing Date
PT80239A PT80239B (pt) 1984-04-06 1985-04-04 Processo para a preparacao de novos polipeptideos fisiologicamente activos no homem e de composicoes farmaceuticas que os contem

Country Status (39)

Country Link
US (1) US4879226A (h)
EP (2) EP0354592A1 (h)
JP (1) JPS60252496A (h)
KR (1) KR920007399B1 (h)
AR (1) AR240475A1 (h)
AU (2) AU595480B2 (h)
BE (1) BE902119A (h)
BG (1) BG43355A3 (h)
BR (1) BR8501624A (h)
CA (1) CA1341348C (h)
CH (2) CH672790A5 (h)
DD (1) DD251785A5 (h)
DK (1) DK151985A (h)
EG (1) EG17965A (h)
ES (1) ES8704976A1 (h)
FI (1) FI86992C (h)
FR (1) FR2564097B1 (h)
GB (1) GB2158829B (h)
GR (1) GR850836B (h)
HK (1) HK102192A (h)
HU (1) HUT37813A (h)
IE (1) IE58833B1 (h)
IL (1) IL74804A (h)
IN (1) IN163653B (h)
IT (1) IT1218469B (h)
JO (1) JO1365B1 (h)
LU (1) LU85835A1 (h)
MA (1) MA20402A1 (h)
MT (1) MTP963B (h)
MY (1) MY101887A (h)
NO (1) NO174473C (h)
NZ (2) NZ231317A (h)
OA (1) OA07983A (h)
PL (1) PL156392B1 (h)
PT (1) PT80239B (h)
RO (1) RO93650B (h)
SG (1) SG77892G (h)
YU (1) YU57885A (h)
ZA (1) ZA852563B (h)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
JP2584206B2 (ja) * 1984-08-17 1997-02-26 大日本製薬株式会社 ヒト癌壊死因子
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPS60228297A (ja) * 1984-04-24 1985-11-13 株式会社　東京タツノ 給油装置
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
GR851626B (h) * 1984-07-05 1985-11-26 Genentech Inc
AU589919B2 (en) * 1984-10-15 1989-10-26 Cetus Corp Human tumor necrosis factor
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
WO1986003751A2 (en) * 1984-12-21 1986-07-03 Biogen N.V. Purification, production and use of tumor necrosis factors
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
IE59814B1 (en) * 1986-07-31 1994-04-06 Genentech Inc Method and composition for the prophylaxis and treatment of retroviral infections
DE3716513A1 (de) * 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
US5071834A (en) * 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
US5342613A (en) * 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
CA2003981C (en) * 1988-12-27 2000-06-13 Hiroshi Ishimaru Pharmaceutical compositions and use thereof in the treatment of psoriasis
CA2053864C (en) * 1989-02-21 2001-11-20 Irving Boime Modified forms of reproductive hormones
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
DK0491878T3 (da) 1989-08-16 1997-06-23 Chiron Corp Præparater til inhibering af proteinhormondannelse og anvendelser deraf
ATE199398T1 (de) * 1989-10-24 2001-03-15 Chiron Corp Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5733742A (en) 1993-06-03 1998-03-31 Therapeutic Antibodies Inc. Production of antibody fragments from whole blood
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
NZ302638A (en) 1995-03-16 2001-04-27 Imutec Pharma Inc Immunomodulating composition from bile for the treatment of immune system disorders
FR2733421B1 (fr) * 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20040198819A1 (en) * 2001-06-20 2004-10-07 Young Aiping H. Biological response modifier composition and uses thereof
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP2168603A1 (en) 2003-11-14 2010-03-31 GenVec, Inc. Therapeutic regimen for treating cancer
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
EP2742127B1 (en) 2011-08-12 2019-10-09 Mello Biotechnology, Inc. Inducable expression from the eukaryotic pol-2 promoter in prokaryotes
US10196662B2 (en) 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
ES2885423T3 (es) 2013-02-07 2021-12-13 Massachusetts Gen Hospital Procedimientos para la expansión o el empobrecimiento de células T reguladoras
KR102393711B1 (ko) 2013-10-17 2022-05-04 더 제너럴 하스피탈 코포레이션 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3896084A1 (en) 2016-11-09 2021-10-20 Philogen S.p.A. Immunoconjugates comprising il-2, anti-fibronectin antibody and mutant tnf-alpha

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4359415A (en) * 1981-06-03 1982-11-16 University Of Tennessee Research Corporation Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
JPS6011890B2 (ja) * 1981-12-21 1985-03-28 株式会社林原生物化学研究所 ツモアネクロシスフアクタ−の製造方法
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
JPS57140725A (en) * 1981-12-28 1982-08-31 Dainippon Pharmaceut Co Ltd Physiologically active substance having carcinostatic action
JPS58141785A (ja) * 1982-02-16 1983-08-23 Nippon Shinyaku Co Ltd 抗腫瘍物質の製法
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
HU189251B (en) * 1982-04-07 1986-06-30 Asahi Kasei Kogyo Kk,Jp Process for stabilizing tumor necrosis factor
JPS591288A (ja) * 1982-06-29 1984-01-06 Sato :Kk 連続値札印字装置
AU8956582A (en) * 1982-10-06 1984-04-24 Makitsubo, T. Process for extracting tumor necrosis factor from macrophage
JPS59169492A (ja) * 1983-03-15 1984-09-25 Asahi Chem Ind Co Ltd ヒト融合細胞からの生理活性物質の産生方法
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
JPS5943617Y2 (ja) * 1983-08-26 1984-12-25 株式会社潤工社 広い周波数帯域において均一な特性を有する伝送線路用導体
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
JPS60260522A (ja) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd 遺伝子組換体が生産する生理活性物質の安定化法
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法

Also Published As

Publication number Publication date
NZ231317A (en) 1991-01-29
PT80239A (en) 1985-05-01
FI86992C (fi) 1992-11-10
YU57885A (en) 1989-02-28
FR2564097B1 (fr) 1989-09-22
RO93650A (ro) 1988-03-30
JO1365B1 (en) 1986-11-30
CH675423A5 (h) 1990-09-28
ES8704976A1 (es) 1987-05-01
JPS60252496A (ja) 1985-12-13
HUT37813A (en) 1986-02-28
GB2158829A (en) 1985-11-20
DK151985A (da) 1985-10-07
PL252807A1 (en) 1986-02-25
BE902119A (fr) 1985-10-04
FI86992B (fi) 1992-07-31
OA07983A (en) 1987-01-31
JPH025760B2 (h) 1990-02-05
MTP963B (en) 1985-11-25
US4879226A (en) 1989-11-07
MY101887A (en) 1992-02-15
EG17965A (en) 1994-01-30
IE58833B1 (en) 1993-11-17
AU4088285A (en) 1985-10-10
AU4016289A (en) 1989-12-07
BG43355A3 (en) 1988-05-16
IN163653B (h) 1988-10-22
SG77892G (en) 1992-10-02
DD251785A5 (de) 1987-11-25
HK102192A (en) 1992-12-24
DK151985D0 (da) 1985-04-03
BR8501624A (pt) 1985-12-03
FI851336A0 (fi) 1985-04-03
EP0354592A1 (en) 1990-02-14
ZA852563B (en) 1986-05-28
IE850863L (en) 1985-10-06
FI851336L (fi) 1985-10-07
GB2158829B (en) 1992-04-22
AU595480B2 (en) 1990-04-05
NO174473C (no) 1994-05-11
PL156392B1 (pl) 1992-03-31
KR850007273A (ko) 1985-12-02
CA1341348C (en) 2002-03-19
FR2564097A1 (fr) 1985-11-15
NO174473B (no) 1994-01-31
ES541920A0 (es) 1987-05-01
NZ211666A (en) 1990-01-29
IL74804A0 (en) 1985-07-31
LU85835A1 (fr) 1985-12-16
EP0158286A3 (en) 1987-05-13
GR850836B (h) 1985-06-26
GB8508864D0 (en) 1985-05-09
AU637054B2 (en) 1993-05-20
RO93650B (ro) 1988-03-31
NO851400L (no) 1985-10-07
CH672790A5 (h) 1989-12-29
AR240475A1 (es) 1990-04-30
IL74804A (en) 1991-06-30
KR920007399B1 (ko) 1992-08-31
MA20402A1 (fr) 1985-12-31
IT1218469B (it) 1990-04-19
IT8520242A0 (it) 1985-04-05
EP0158286A2 (en) 1985-10-16

Similar Documents

Publication Publication Date Title
PT80239B (pt) Processo para a preparacao de novos polipeptideos fisiologicamente activos no homem e de composicoes farmaceuticas que os contem
PT81746B (pt) Processo para a preparacao de peptido-aldeidos e de composicoes farmaceuticas que os contem
PT84569B (pt) Processo para a preparacao de tiazepinas e de composicoes farmaceuticas que os contem
PT81969B (pt) Processo para preparacao de 11 beta-fenil-esteroides e de composicoes farmaceuticas que os contem
PT89009A (pt) Processo para a preparacao de novos derivados de fluorocitidina e composicoes farmaceuticas que os contem
PT80892B (pt) Processo para a preparacao de derivados da quoinona e de composicoes farmaceuticas que os contem
PT78732A (pt) Processo para a preparacao de 13 alpha-alquilgonanos e de composicoes farmaceuticas que os contem
PT86399A (pt) Processo para a preparacao de hidrossoles de agentes farmacologicamente activos e de composicoes que os contem
PT82460B (pt) Processo para a preparacao de novos derivados de imidazoquinolina com actividade cardiotonica antitrombogenica e de composicoes farmaceuticas que os contem
PT81041B (pt) Processo para a preparacao de derivados de etilenodiamina-monoamida e de composicoes farmaceuticas que os contem
PT82985B (pt) Processo para a preparacao de derivados de distamicina e de composicoes farmaceuticas que os contem
PT81636B (pt) Processo para a preparacao de novos benzotiofenos e benzofurados e de composicoes farmaceuticas que os contem
PT80363B (pt) Processo para a preparacao de derivados de fenol e de composicoes farmaceuticas que os contem
PT93060A (pt) Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
PT90142A (pt) Processo para a preparacao de novos imidazois substituidos em 2,3 e 4 e de 1,2,4-triazois substituido4 em 3,4 e 5 bem como de composicoes farmaceuticas que os contem
PT80246B (pt) Processo para a preparacao de novos derivados de cefalosporina e de composicoes farmaceuticas que os contem
PT81659B (pt) Processo para a preparacao de aminoacil-labdanos e de composicoes farmaceuticas que os contem
PT78986A (pt) Processo para a preparacao de derivados basicos de cumarina e de composicoes farmaceuticas que os contem
PT82984B (pt) Processo para a preparacao de derivados de poli-4-aminopirrole-2-carboxamido e de composicoes farmaceuticas que os contem
PT84064B (pt) Processo para a preparacao de novos derivados de aminoacidos e de composicoes farmaceuticas que os contem
PT84358B (pt) Processo para a preparacao de naftotiazepinonas e de composicoes farmaceuticas que as contem
PT91122A (pt) Processo para a preparacao de novos derivados amidinicos e guanidinicos e de composicoes farmaceuticas que os contem
PT80794B (pt) Processo para a preparacao de novas isoindolinil-alquilpiperazinas e de composicoes farmaceuticas que as contem
PT82399B (pt) Processo para a preparacao de derivados de fenetanolamina e de composicoes farmaceuticas que os contem
PT87090A (pt) Processo para a preparacao de derivados de imidazopiridinas e de composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19960229